Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation

Fertility and Sterility

Volumn 100, Issue 2, 2013, Pages 538-543

  Tal, Reshef ^a   Seifer, David B ^a   Shohat Tal, Aya ^b   Grazi, Richard V ^a   Malter, Henry E ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

angiogenesis; controlled ovarian stimulation (COS); Polycystic ovarian syndrome (PCOS); soluble endoglin (sENG); transforming growth factor 1 (TGF 1)

Indexed keywords

CHORIONIC GONADOTROPIN; ENDOGLIN; ESTROGEN; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN; MUELLERIAN INHIBITING FACTOR; RECOMBINANT FOLLITROPIN; SOLUBLE ENDOGLIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOAVAILABILITY; BODY MASS; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED OVARIAN STIMULATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HORMONAL THERAPY; HUMAN; OOCYTE RETRIEVAL; OVARY FOLLICLE FLUID; OVARY POLYCYSTIC DISEASE; OVULATION; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TRANSVAGINAL ECHOGRAPHY;

ANGIOGENESIS; CONTROLLED OVARIAN STIMULATION (COS); POLYCYSTIC OVARIAN SYNDROME (PCOS); SOLUBLE ENDOGLIN (SENG); TRANSFORMING GROWTH FACTOR-Β1 (TGF-Β1);

ADULT; ANTIGENS, CD; CASE-CONTROL STUDIES; FEMALE; FERTILIZATION IN VITRO; FOLLICULAR FLUID; HUMANS; INFERTILITY, FEMALE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; RECEPTORS, CELL SURFACE; SPERM INJECTIONS, INTRACYTOPLASMIC; TRANSFORMING GROWTH FACTOR BETA1; YOUNG ADULT;

EID: 84881191708     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2013.04.022     Document Type: Article

References (42)

1. R.J. Norman, D. Dewailly, R.S. Legro, and T.E. Hickey Polycystic ovary syndrome Lancet 370 2007 685 697
2. V. Padmanabhan Polycystic ovary syndrome - "A riddle wrapped in a mystery inside an enigma" J Clin Endocrinol Metab 94 2009 1883 1885
3. J. Qiao, and H.L. Feng Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence Hum Reprod Update 17 2011 17 33
4. C.K. Welt, A.E. Taylor, J. Fox, G.M. Messerlian, J.M. Adams, and A.L. Schneyer Follicular arrest in polycystic ovary syndrome is associated with deficient inhibin A and B biosynthesis J Clin Endocrinol Metab 90 2005 5582 5587
5. R. Fleming, L. Harborne, D.T. MacLaughlin, D. Ling, J. Norman, and N. Sattar Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment Fertil Steril 83 2005 130 136
6. T. Eldar-Geva, I.M. Spitz, N.P. Groome, E.J. Margalioth, and R. Homburg Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome Hum Reprod 6 2001 2552 2556
7. I. Sozen, and A. Arici Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata Fertil Steril 78 2002 1 12
8. M. Laiho, J.A. DeCaprio, J.W. Ludlow, D.M. Livingston, and J. Massague Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation Cell 62 1990 175 185
9. D.J. Satterwhite, and H.L. Moses Mechanisms of transforming growth factor-beta 1-induced cell cycle arrest Invasion Metastasis 14 1994 309 318
10. E.Y. Yang, and H.L. Moses Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane J Cell Biol 111 1990 731 741
11. R. Govinden, and K.D. Bhoola Genealogy, expression, and cellular function of transforming growth factor-beta Pharmacol Ther 98 2003 257 265
12. G.J. Prud'homme Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations Lab Invest 87 2007 1077 1091
13. N. Chegini TGF-beta system: the principal profibrotic mediator of peritoneal adhesion formation Semin Reprod Med 26 2008 298 312
14. P.E. Hughesdon Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called "hyperthecosis" Obstet Gynecol Surv 37 1982 59 77
15. R. Agrawal, P. Sladkevicius, L. Engmann, G.S. Conway, N.N. Payne, and J. Bekis Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries Hum Reprod 13 1998 651 655
16. N. Raja-Khan, A.R. Kunselman, L.M. Demers, K.G. Ewens, R.S. Spielman, and R.S. Legro A variant in the fibrillin-3 gene is associated with TGF-beta and inhibin B levels in women with polycystic ovary syndrome Fertil Steril 94 2010 2916 2919
17. M. Urbanek, S. Sam, R.S. Legro, and A. Dunaif Identification of a polycystic ovary syndrome susceptibility variant in fibrillin-3 and association with a metabolic phenotype J Clin Endocrinol Metab 92 2007 4191 4198
18. K.G. Ewens, D.R. Stewart, W. Ankener, M. Urbanek, J.M. McAllister, and C. Chen Family-based analysis of candidate genes for polycystic ovary syndrome J Clin Endocrinol Metab 95 2010 2306 2315
19. E.R. Neptune, P.A. Frischmeyer, D.E. Arking, L. Myers, T.E. Bunton, and B. Gayraud Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome Nat Genet 33 2003 407 411
20. S. Nakerakanti, and M. Trojanowska The role of TGF-beta receptors in fibrosis Open Rheumatol J 6 2012 156 162
21. S.E. Duff, C. Li, J.M. Garland, and S. Kumar CD105 is important for angiogenesis: evidence and potential applications FASEB J 17 2003 984 992
22. R.J. Levine, C. Lam, C. Qian, K.F. Yu, S.E. Maynard, and B.P. Sachs Soluble endoglin and other circulating antiangiogenic factors in preeclampsia N Engl J Med 355 2006 992 1005
23. S. Venkatesha, M. Toporsian, C. Lam, J. Hanai, T. Mammoto, and Y.M. Kim Soluble endoglin contributes to the pathogenesis of preeclampsia Nat Med 12 2006 642 649
24. N.K. Kapur, S. Wilson, A.A. Yunis, X. Qiao, E. Mackey, and V. Paruchuri Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure Circulation 125 2012 2728 2738
25. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome Fertil Steril 81 2004 19 25
26. M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, and J.J. Espinos Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome Hum Reprod Update 11 2005 375 390
27. Z.L. Miao, L. Guo, Y.X. Wang, R. Cui, N. Yang, and M.Q. Huang The intervention effect of Rosiglitozone in ovarian fibrosis of PCOS rats Biomed Environ Sci 25 2012 46 52
28. C. Laviades, N. Varo, and J. Diez Transforming growth factor beta in hypertensives with cardiorenal damage Hypertension 36 2000 517 522
29. M. Romano, M.T. Guagnano, G. Pacini, S. Vigneri, A. Falco, and M. Marinopiccoli Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women J Clin Endocrinol Metab 88 2003 5321 5326
30. A. Pfeiffer, K. Middelberg-Bisping, C. Drewes, and H. Schatz Elevated plasma levels of transforming growth factor-beta 1 in NIDDM Diabetes Care 19 1996 1113 1117
31. X.L. Wang, S.X. Liu, and D.E. Wilcken Circulating transforming growth factor beta 1 and coronary artery disease Cardiovasc Res 34 1997 404 410
32. S. Sam, and A. Dunaif Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 14 2003 365 370
33. M. Urbanek, R.S. Legro, D.A. Driscoll, R. Azziz, D.A. Ehrmann, and R.J. Norman Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin Proc Natl Acad Sci U S A 96 1999 8573 8578
34. M.R. Jones, S.G. Wilson, B.H. Mullin, R. Mead, G.F. Watts, and B.G. Stuckey Polymorphism of the follistatin gene in polycystic ovary syndrome Mol Hum Reprod 13 2007 237 241
35. N. Ferrara, G. Frantz, J. LeCouter, L. Dillard-Telm, T. Pham, and A. Draksharapu Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries Am J Pathol 162 2003 1881 1893
36. P.G. Artini, M. Monti, C. Matteucci, V. Valentino, F. Cristello, and A.R. Genazzani Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation Gynecol Endocrinol 22 2006 465 470
37. A.F. Amin, D.E. Abd el-Aal, A.M. Darwish, and A.R. Meki Evaluation of the impact of laparoscopic ovarian drilling on Doppler indices of ovarian stromal blood flow, serum vascular endothelial growth factor, and insulin-like growth factor-1 in women with polycystic ovary syndrome Fertil Steril 79 2003 938 941
38. S.R. Soares, R. Gomez, C. Simon, J.A. Garcia-Velasco, and A. Pellicer Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome Hum Reprod Update 14 2008 321 333
39. A. Pellicer, C. Albert, A. Mercader, F. Bonilla-Musoles, J. Remohi, and C. Simon The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor Fertil Steril 71 1999 482 489
40. H. Higashiyama, D. Yoshimoto, T. Kaise, S. Matsubara, M. Fujiwara, and H. Kikkawa Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis Exp Mol Pathol 83 2007 39 46
41. J.A. Moon, H.T. Kim, I.S. Cho, Y.Y. Sheen, and D.K. Kim IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy Kidney Int 70 2006 1234 1243
42. N.J. Laping, J.I. Everitt, K.S. Frazier, M. Burgert, M.J. Portis, and C. Cadacio Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats Clin Cancer Res 13 2007 3087 3099